ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO547

Diagnostic Performance of a Unique Fragment of Human Fetuin-A for Patients Undergoing Native Kidney Biopsy

Session Information

  • Pathology and Lab Medicine
    November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pathology and Lab Medicine

  • 1700 Pathology and Lab Medicine


  • Tsai, Ming-Tsun, Taipei Veterans General Hospital, Taipei, Taiwan, Taiwan
  • Tseng, Wei-Cheng, Taipei Veterans General Hospital, Taipei, Taiwan, Taiwan
  • Tseng, Tzu-Ling, Bio Preventive Medicine Corp., Hsinchu, Taiwan

Fetuin-A is a hepatokine secreted into the systemic circulation and regulates many biological processes. The relationship between fetuin-A and progression of chronic kidney disease (CKD) has been studied intensively, but its role in CKD and its complications remains to be clarified. Several types of post-translational modifications (PTMs) on fetuin-A are identified in patients with CKD, implying the possible effects of these modifications on renal structure and function.


A commercial immunoassay, DNlite-IVD103 supplied by Bio Preventive Medicine Corp., was used to measure urine levels of a unique PTM fetuin-A (uPTM-Fet-A) in a cohort of patients undergoing native kidney biopsies. Relationships between uPTM-Fet-A, clinical characteristics, and tubulointerstitial damage were analyzed with logistic regression. Furthermore, the accuracy of the uPTM-Fet-A in predicting the severity of tubulointerstitial fibrosis was evaluated by constructing receiver operating characteristic curves.


To analyze the relationship between uPTM-Fet-A and clinical features, we divided the patients into two groups according to median levels of uPTM-Fet-A (65.6 ng/mg). The high-level group had a larger percentage of elderly male patients and patients with decreased renal function, higher levels of proteinuria, and severe renal fibrosis than the low-level group. After multivariate adjustment, renal impairment, hypoalbuminemia, and high-grade proteinuria were independently correlated with elevated levels of uPTM-Fet-A. Moremore, compared with the urine protein-to-creatinine ratio (uPCR), uPTM-Fet-A had a better performance in the diagnosis of different extents of renal fibrosis.


Our results suggested that uPTM-Fet-A may be a potential diagnostic biomarker for patients with CKD.

ROC curve analyses comparing the predictability in distinguishing the different grades of IFTA of the uPTM-Fet-A/Cre (ng/mg) with uPCR (mg/mg). The area under the curve (AUC) represents the probability to discriminate the presence of > 10% (A), > 25% (B), or > 50% (C) IFTA in the tissue samples.


  • Government Support – Non-U.S.